The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Rapamycin Resistance Tied to Defective Regulation of p27 Kip1
Open accessAbstract
The potent antiproliferative activity of the macrolide antibiotic rapamycin is known to involve binding of the drug to its cytosolic receptor, FKBP12, and subsequent interaction with targets of rapamycin, resulting in inhibition of p70 S6 kinase (p70S6K). However, the downstream events that lead to inhibition of cell cycle progression remain to be elucidated. The antiproliferative effects of rapamycin are associated with prevention of mitogen-induced downregulation of the cyclin-dependent kinase inhibitor p27Kip1, suggesting that the latter may play an important role in the growth pathway targeted by rapamycin. Murine BC3H1 cells, selected for resistance to growth inhibition by rapamycin, exhibited an intact p70S6K pathway but had abnormally low p27 levels that were no longer responsive to mitogens or rapamycin. Fibroblasts and T lymphocytes from mice with a targeted disruption of the p27Kip1 gene had impaired growth-inhibitory responses to rapamycin. These results suggest that the ability to regulate p27Kip1 levels is important for rapamycin to exert its antiproliferative effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Chemistry and Biology of the Immunophilins and Their Immunosuppressive Ligands
Schreiber, S. L. (1991) · Science · doi:10.1126/science.1702904 · Cited by 1,494 · cited 13×
“Rapamycin acts by binding to the cytosolic protein FKBP12 (46), and this complex in turn binds to and inhibits FRAP (4).”
BackgroundInfluentialAlbers, M. W., Williams, R. T., Brown, E. J., Tanaka, A., Hall, F. L., & Schreiber, S. L. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41602-x · Cited by 145
Cited by
TOR, a Central Controller of Cell Growth
Schmelzle, T., & Hall, M. N. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 1,924
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k
Jefferies, H. B. J., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B., & Thomas, G. (1997) · The EMBO Journal · doi:10.1093/emboj/16.12.3693 · Cited by 934
mTOR-targeted therapy of cancer with rapamycin derivatives
Vignot, S., Faivre, S., Aguirre, D., & Raymond, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi113 · Cited by 617
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
Hidalgo, M., & Rowinsky, E. K. (2000) · Oncogene · doi:10.1038/sj.onc.1204091 · Cited by 582
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/−mice
Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 569
Gallo, R., Padurean, A., Jayaraman, T., Marx, S., Roque, M., Adelman, S., Chesebro, J., Fallon, J., Fuster, V., Marks, A., et al. (1999) · Circulation · doi:10.1161/01.cir.99.16.2164 · Cited by 490
Self-citationTOR signalling and control of cell growth
Thomas, G., & Hall, M. N. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80078-6 · Cited by 462
Bench to Bedside: The Development of Rapamycin and Its Application to Stent Restenosis
Marx, S. O., & Marks, A. R. (2001) · Circulation · doi:10.1161/01.cir.104.8.852 · Cited by 447
Self-citationUse of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy
Mancini, D., Pinney, S., Burkhoff, D., LaManca, J., Itescu, S., Burke, E., Edwards, N., Oz, M., & Marks, A. R. (2003) · Circulation · doi:10.1161/01.cir.0000070421.38604.2b · Cited by 442
Self-citationCell-cycle inhibitors: three families united by a common cause
Vidal, A., & Koff, A. (2000) · Gene · doi:10.1016/s0378-1119(00)00092-5 · Cited by 431
Self-citationTargeted Disruption of CDK4 Delays Cell Cycle Entry with Enhanced p27 Kip1 Activity
Tsutsui, T., Hesabi, B., Moons, D. S., Pandolfi, P. P., Hansel, K. S., Koff, A., & Kiyokawa, H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.7011 · Cited by 395
Self-citationHypoxia Inhibits G1/S Transition through Regulation of p27 Expression
Gardner, L. B., Li, Q., Park, M. S., Flanagan, W. M., Semenza, G. L., & Dang, C. V. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010189200 · Cited by 390
Pestell, R. G., Albanese, C., Reutens, A. T., Segall, J. E., Lee, R. J., & Arnold, A. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.4.0373 · Cited by 375
Kolluri, S. K., Weiss, C., Koff, A., & Gottlicher, M. (1999) · Genes & Development · doi:10.1101/gad.13.13.1742 · Cited by 364
Self-citationVascular Smooth Muscle Cell Proliferation in Restenosis
Marx, S. O., Totary-Jain, H., & Marks, A. R. (2011) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.110.957332 · Cited by 354
Self-citationHashemolhosseini, S., Nagamine, Y., Morley, S. J., Desrivières, S., Mercep, L., & Ferrari, S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14424 · Cited by 342
Signaling by Target of Rapamycin Proteins in Cell Growth Control
Inoki, K., Ouyang, H., Li, Y., & Guan, K.-L. (2005) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.69.1.79-100.2005 · Cited by 330
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Franklin, R. A., Montalto, G., Cervello, M., Libra, M., Candido, S., Malaponte, G., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.659 · Cited by 314
Cordon-Cardo, C., Koff, A., Drobnjak, M., Capodieci, P., Osman, I., Millard, S. S., Gaudin, P. B., Fazzari, M., Zhang, Z.-F., Massague, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.17.1284 · Cited by 300
Self-citationNew Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors
FAIVRE, S., DJELLOUL, S., & RAYMOND, E. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.005 · Cited by 264
T Cells Deficient in Inositol 1,4,5-Trisphosphate Receptor Are Resistant to Apoptosis
Jayaraman, T., & Marks, A. R. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.6.3005 · Cited by 257
Self-citationCurcumin inhibits the mammalian target of rapamycin‐mediated signaling pathways in cancer cells
Beevers, C. S., Li, F., Liu, L., & Huang, S. (2006) · International Journal of Cancer · doi:10.1002/ijc.21932 · Cited by 256
Rapamycin: an anti-cancer immunosuppressant?
Law, B. K. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.009 · Cited by 252
Signal-transduction cascades as targets for therapeutic intervention by natural products
Cardenas, M. E., Sanfridson, A., Cutler, N. S., & Heitman, J. (1998) · Trends in Biotechnology · doi:10.1016/s0167-7799(98)01239-6 · Cited by 101
Peeper, D. S., & Bernards, R. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00319-0 · Cited by 36
Metadata
- Authors
- Luo, Y., Marx, S. O., Kiyokawa, H., Koff, A., Massagué, J., & Marks, A. R.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1996-12
- Volume
- 16
- Issue
- 12
- Pages
- 6744-6751
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2151559596
- Cited by
- 210
- References
- 3
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.